Center of Excellence in Pharmacokinetics and Pharmacodynamics
- Provision of annual continuing education courses and workshops in areas such as Pharmacokinetics and Pharmacodynamics. Co-sponsorship of affiliated workshops with the Center for Protein Therapeutics on Monoclonal Antibody PK/PD using ADAPT, with the Cognigen Corporation on Population Modeling, and with Daniel Weiner on Phoenix (May courses in Niagara Falls).
- Provision of 1–2-day workshops on pharmacometrics and software applications provided by outside experts and software companies during the academic year primarily for graduate students and post-docs.
- Affiliations with software providers such as Certara/Phoenix and SimulationsPlus to gain complementary use of state-of-the-art commercial software for various applications in pharmacometrics and to access their funding mechanisms.
- Serving as a resource for pharmaceutical companies and other academic institutes that seek training sites for graduate students, post-doctoral fellows, and visiting scientific staff (e.g. Pfizer, Bristol Meyers Squib, Teijin).
- Promoting collaborative research projects and grant applications (e.g. formerly NIH GM 57980, Mathematical Models in Pharmacodynamics).
- Promoting relationships with local pharmacometric providers such as Cognigen Corporation, the Institute for Clinical Pharmacodynamics, and Enhanced Pharmacodynamics LLC (ePD), as well as numerous other computational companies partly to serve as training, internship, and job sites for BS, MS, and PhD students.
- Joint sponsorship of PK/PD workshops and research collaborations with international institutes (such as in Ireland in 2016, Adapt workshops in Poland, the June and Nov. 2019 PK/PD courses in Shanghai and Beijing, and the research agreement with the Drug Trial Clinical Center, Peking University Third Hospital, Beijing, China).
- Providing emphasis of a major departmental strength in recruiting the top graduate students and post-doctoral fellows, particularly for the new MS degree in Pharmacometrics and Personalized Therapeutics.